Preface – EANM 2023
© Institut Jules Bordet – Magdalena Mileva, MD, Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium
Dear Colleagues,
The 36th annual congress of the European Association of Nuclear Medicine (EANM) was held in Vienna, Austria, and virtually from 9th to 13th September. As always, the very much-anticipated event brought more than 7,600 leading experts from across the globe together to learn and discuss the groundbreaking updates and scientific advancements in nuclear medicine, which were covered in nearly 2,000 oral presentations and e-posters in 156 sessions.
The first chapter of this memo inOncology report sets the stage for groundbreaking new developments in the diagnosis of neuroendocrine tumors (NETs) and spotlights innovative approaches utilizing SSTR-antagonists such as 68Ga-DATA5m-LMA, [18F]-AlF-NOTA-LM3, [68Ga]Ga-DATA5m-LM4 or [99mTc]Tc-TECANT 1 radiotracers.
Subsequently, the latest advancements in NETs are highlighted with emphasis on combining radioligand therapy with standard treatments in patients with progressive advanced non-resectable gastroenteropancreatic NETs. Moreover, the utility of 177Lu-DOTATATE following peptide receptor radionuclide therapy (PRRT) in patients with bronchopulmonary neuroendocrine neoplasms and a personalized PRRT-regime using tailored 177Lu-DOTATATE activity in patients with overexpressing SSTR NETs are outlined.
The section on NET theranostics overviews the interim data of the first-in-class alpha-emitting radiopharmaceutical 225Ac-DOTATATE, data gleaned from a human pilot study with 212Pb-VMT-α-NET, as well as the promising prospects of personalized dosimetry-based PRRT, combining mixed doses of [177Lu]Lu- and [90Y]Y-DOTATATE. It further delves deeper into assessing the predictive potential of full-body longitudinal somatostatin receptor imaging features for predicting clinical outcomes in metastatic NET patients receiving PRRT.
Within the realm of prostate cancer, we witness the transformative potential of non-invasive nuclear medicine techniques, offering both diagnostic and targeted therapeutic solutions. Thus, this report accentuates the early prediction of response to 177Lu-PSMA therapy with 68Ga-PSMA or the new class of 18F-rhPSMA-7.3 PET/CT. Additionally, interim data on the utility of 18F-PSMA-1007 as a surrogate marker for 177Lu-PSMA imaging and treatment effectiveness are summarized.
Furthermore, this special issue encompasses the encouraging advances in PSMA-based therapy in metastatic castration resistant prostate cancer, including insights from the phase III ProstACT GLOBAL study, findings from the phase II IRST-185.03, an overview of the prospective national Swiss registry assessing 177Lu-PSMA for imaging and therapy, as well as a compilation of results from different combinations of 225Ac-TAT/177Lu-PSMA-I&T.
Finally, the section regarding further benefits of PET imaging in prostate cancer covers results from the VISION and the LuTectomy trial, while further discussing the implementation of PSMA-PET imaging after prostate cancer salvage radiotherapy in recurrent or persistent prostate cancer patients after surgery.
Once again, the EANM congress was not only a platform for exchanging groundbreaking scientific insights but also continued to bolster our growth as a specialist community. With the data presented, it is needless to say that the present of nuclear medicine is bright, and that the future holds even greater promise.
I hope you enjoy reading this special issue!
More posts
Gerrina Ruiter
WCLC 2024 - Gerrina Ruiter Gerrina Ruiter dives into the exciting world of HER2, exp ...
Refining treatment approaches in early-stage lung cancer
At WCLC 2024, Cascone et al. reported preliminary efficacy and safety data for several novel perioperative combinations in patients with stage IIA-IIIB resectable non–small-cell lung cancer (NSCLC) included in Arms 1, 2 and 4 of the open-label, phase II NeoCOAST-2 platform study [1].
Diego Kauffmann-Guerrero
WCLC 2024 - Diego Kauffmann-Guerrero Diego Kauffmann-Guerrero provides insights into ...
Innovative treatment approaches: non–EGFR-directed bispecific antibodies and ADCs
In the management of patients with advanced PD-L1–positive non–small-cell lung cancer (NSCLC), the use of bispecific antibodies is gaining ground. Ivonescimab (AK112) is a first-in-class bispecific antibody directed against PD-1 and the vascular endothelial growth factor (VEGF) type A. As VEGF and PD-(L)1 inhibitors were found to have synergistic activity, it was postulated that their simultaneous use might enhance treatment efficacy compared with the co-administration of separate anti–PD-(L)1 and anti-VEGF agents [1-3].
HER2 aberrations and other oncogenic drivers
HER2 mutations are rare as they occur in approximately 2–4 % of NSCLC cases, although they are associated with poor prognosis and increased incidence of brain metastases [1, 2]. As HER2-mutant NSCLC is relatively insensitive to chemotherapy, there is a substantial unmet need for targeted options [3, 4].
Concurrent MET/EGFR inhibition and third-generation EGFR TKIs
The EGFR-MET bispecific antibody amivantamab in addition to the third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib has shown favorable results as first-line treatment compared to osimertinib in the ongoing randomized, double-blind, phase III MARIPOSA trial. A total of 1,074 patients from 27 countries with advanced non–small-cell lung cancer (NSCLC) and activating EGFR mutations were enrolled in the study.